ClinicalTrials.gg
Active, not recruitingNCT07785869Updated Aug 25, 2026

Effects of a Topical Serum Solution on Hair Characteristics

An interventional study of Re:You Hair Revival Serum 1 and Re:You Hair Revival Serum 2 in Hair Characteristics, sponsored by Pacagen, Inc.. Active, not recruiting at 3 sites in 2 countries. Open to female participants aged 35 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by Pacagen, Inc. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Jan 2026, registered Aug 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
190
Allocation
Randomized
Ages
35 Years to 70 Years
Sex
Female
01

Study summary

The purpose of this study is to assess changes in the characteristics of scalp hair among healthy female participants with mild to moderate hair loss, classified as Ludwig Scale I-3 to II-2

Read the detailed description

This study will include healthy female participants with mild to moderate hair loss of the scalp, classified as Ludwig Scale I-3 to II-2. Approximately 190 eligible participants will be enrolled to ensure 150 participants complete the study. Eligible individuals will be selected from the participating test facility's database of registered healthy volunteers. Participants will be randomized to use either Re:You Revival Hair Serum 1 (Product A), Re:You Hair Revival Serum 2 (Product B), or Topical Minoxidil 2% for 6 months using a computer-generated randomization table. Study participants will use the test product they have been randomized to daily for 6 months.

This study plans to assess whether daily application of a topical solution to the scalp for six months will improve hair characteristic like growth, retention, thickness, and scalp coverage, and whether daily application results in favorable consumer perception compared with baseline and the study control product.

The main purpose of the study is to assess global changes to scalp hair as graded by trained expert clinical graders, focusing on hair thickness/volume. Furthermore, each participant will perform a standardized comb test to determine the number of fallen hair after combing. Participants will also be asked to complete a questionnaire which assess their perception of hair characteristics and satisfaction with the test product they used during the study.

For a subset of participants digital imaging with software analyses of hair characteristics will be performed. The digital imaging software measures hair characteristics like hair density, hair thickness, target area hair coverage, and hair length.

Safety data will be collected throughout the study duration for each participant who received at least one application of test product.

In this study the per-protocol (PP) population will be the primary population for all statistical analyses. The PP population will include all subjects who received treatment, completed the study in general accordance with the protocol, and have undergone expert clinical grading.

Study Rational: Approximately, 40% of women suffer from female pattern hair loss by the age of 55. Currently, there is only one drug approved by the US FDA for the treatment of female pattern hair loss (AGA) - topical minoxidil. While topical minoxidil exhibits a good safety profile, the efficacy in the overall population is relatively low i.e., 30-40% re-grow hair.

Minoxidil is a pro-drug. To elicit a clinical response, minoxidil must be converted to its active form minoxidil sulfate by a sulfotransferase enzyme found in hair follicles. Individuals with low enzymatic activity experience little or no therapeutic benefit.

RE:YOU Hair Revival Serum is a non-drug, non-hormonal hair serum designed to support hair density, reduce visible shedding, and promote fuller-looking hair. The formula features proprietary NOVOGRO™ molecules designed to support multiple pathways associated with hair follicle and scalp environment health. These molecules support healthy hair follicle activity while helping maintain an optimal scalp environment to support stronger, thicker, and healthier-looking hair over time.

02

Conditions studied

  • Hair Characteristics

Keywords

  • Hair Characteristics
  • Hair Thickness
  • Topical Serum
  • Hair Care
  • Cosmetic Product
03

In context

Lead sponsor

This is the only study on the registry with Pacagen, Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant is female between 35 and 70 years of age;
  2. Participant has mild to moderate hair loss, classified as Ludwig Scale I-3 to II-2;
  3. Participant agrees not to use any hair products other than those required by the protocol (tonic, lacquer, gel, foam, etc.) until the end of the study;
  4. Participant agrees not to change their shampoo, conditioner, or shampooing frequency and maintain a consistent hairstyle for the duration of the study;
  5. Participant is willing to use only their regular, neutral mascara on their eyelashes and stop use of any other products on them for the duration of the study;
  6. Participant is willing to not substantially change their current diet, medications, multivitamins or supplement, or exercise routines for the duration of the study;
  7. Participant is in generally good health;
  8. Participant understands and has signed an Form in conformance with 21 CFR Part 50: "Protection of Human Participants."

Exclusion criteria

Exclusion Criteria:

  1. Participant is pregnant, nursing, planning a pregnancy, or not using adequate ;
  2. Participant wears a weave, extensions or dreadlocks or any other hairstyles that would interfere with the comb test;
  3. Participant exhibits irritation, tattoos, sunburn, rashes, scratches, burn marks, scarring, etc. on the test site, which might interfere with evaluations of test results;
  4. Participant is participating in another clinical study;
  5. Participant has used Minoxidil, Finasteride or any topical and oral supplements or other therapies (such as light therapy) known to prevent or promote hair growth within the past 3 months;
  6. Participant has been taking a stable dose of thyroid medication for a period of less than 4 months;
  7. Participant has been taking a stable dose of GLP-1 (to manage diabetes or weight loss);
  8. Participant has been taking a stable dose of hormonal medication (testosterone/ estrogen/progesterone) for a period of less than 6 months;
  9. Participant has used any devices, prescriptions or OTC drugs that are known to affect the hair growth cycle within the past 6 months;
  10. Participant uses medications known to affect the hair growth cycle within the last months such as cyproterone acetate, aldactone/spironolactone, finasteride, or other 5-alpha-reductase inhibitors;
  11. Participant has received treatment with sympathomimetics, antihistamines, vasoconstrictors, non-steroidal anti-inflammatory agents, and/or systemic or topical within one month prior to initiation of the study;
  12. Participant has a history of acute or chronic dermatologic, medical, and/or physical conditions which would, in the opinion of the Principal Investigator, could influence the outcome of the study;
  13. Participant is currently taking certain medications which, in the opinion of the Principal Investigator, may interfere with the study;
  14. Participant has known allergies to skin treatment products or cosmetics, toiletries, and/or topical drugs;
  15. Participant is currently undergoing treatment for active cancer of any kind;
  16. Participant has uncontrolled diabetes.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
190 participants (actual)

Study arms

  • Experimental
    Re:You Hair Revival Serum 1

    Other: Re:You Hair Revival Serum 1

  • Experimental
    Re:You Hair Revival Serum 2

    Other: Re:You Hair Revival Serum 2

  • Active comparator
    Topical Minoxidil 2% solution

    Drug: Topical Minoxidil 2%

Interventions

  • OtherRe:You Hair Revival Serum 1

    Participants apply 1 mL (equivalent to two dropperfuls) of Re:You Hair Revival Serum 1 once daily to the scalp for 6 months.

    Also known as: Product A, ReYou Sample 1, Product 1

  • OtherRe:You Hair Revival Serum 2

    Participants apply 1 mL (equivalent to two dropperfuls) of Re:You Hair Revival Serum 2 once daily to the scalp for 6 months.

    Also known as: Product B, ReYou Sample 2, Product 2

  • Participants apply 2 mL (equivalent to two dropperfuls) of topical minoxidil 2% solution once daily to the scalp for 6 months.

    Also known as: OTC Product, Control, ReYou Sample 3, Product 3

06

What researchers measure

Primary outcomes

  1. Change from baseline in global scalp hair thickness/volume

    Clinical grading of the thickness of the global scalp hair using a 0-9 scoring scale

    Time frame: Baseline, Day 180

Secondary outcomes

  1. Change from baseline in global scalp hair thickness/volume

    Clinical grading of the thickness of the global scalp hair using a 0-9 scoring scale

    Time frame: Baseline, Day 90

  2. Participant Perception

    Self-administered perception questionnaire, consisting of up to 18 questions in the patient's language on treatment effect on hair characteristics, satisfaction with appearance, self-perceived stress levels, and confidence.

    Time frame: Baseline, Day 90, Day 180

  3. Comb test

    Hair in the target area will be combed onto a white paper for a total of 60 seconds. Hair that falls onto the white surface will be counted

    Time frame: Baseline, Day 90, Day 180

  4. Subgroup analysis: Change from baseline in target area hair thickness

    Thickness of the hair in the target area measured using digital imaging and software analysis. Hair thickness is reported in μm

    Time frame: Baseline, Day 90, Day 180

  5. Adverse Events

    Any undesirable experience associated with the treatment or the comparator in a study participant.

    Time frame: Through study completion

07

Study locations

3 sites
  • Eurofins | CRL, Cosmetics LLC
    Piscataway, New Jersey 08854, United States
  • Eurofins Virginia Site
    Forest, Virginia 24551, United States
  • Eurofins Consumer Product Testing (Guangzhou) Co., Ltd.
    Guangzhou, Guangdong 510289, China
08

References and documents

Publications

  • Qu Z, Li Y, Cho SE, Doğan L, Yao Q, Tang L, Zhao G, Zhao EM, Li A, Omori S, Wong F, Zhang DKY. AI-enabled discovery of small molecules targeting complementary pathways for hair follicle rejuvenation. bioRxiv. June 12, 2026. doi: 10.64898/2026.06.09.728282.

Individual participant data

Plan to share: Yes

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Sep 2026, 7 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2026
First posted
Aug 25, 2026
StartActual
Jan 26, 2026
Primary completionEst.
Sep 25, 2026
CompletionEst.
Sep 25, 2026
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07785869
Lead sponsor
Pacagen, Inc.
Responsible party
Sponsor
First posted
Aug 25, 2026
Start date
Jan 26, 2026
Primary completion
Sep 25, 2026 (estimated)
Completion
Sep 25, 2026 (estimated)
Last update
Aug 25, 2026

Study contacts

Sarah Zeng
principal investigator · Eurofins Consumer Product Testing (Guangzhou) Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion